Xiamen Amoytop Biotech Co Ltd banner
X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 58.25 CNY -1.85% Market Closed
Market Cap: ¥23.8B

EV/IC

7
Current
44%
Cheaper
vs 3-y average of 12.5

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
7
=
Enterprise Value
¥25.7B
/
Invested Capital
¥3.3B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
7
=
Enterprise Value
¥25.7B
/
Invested Capital
¥3.3B

Valuation Scenarios

Xiamen Amoytop Biotech Co Ltd is trading below its 3-year average

If EV/IC returns to its 3-Year Average (12.5), the stock would be worth ¥103.83 (78% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-72%
Maximum Upside
+82%
Average Upside
16%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 7 ¥58.25
0%
3-Year Average 12.5 ¥103.83
+78%
5-Year Average 12.7 ¥105.93
+82%
Industry Average 5.3 ¥43.92
-25%
Country Average 1.9 ¥16.05
-72%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
CN
Xiamen Amoytop Biotech Co Ltd
SSE:688278
23.8B CNY 7 23.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -1 260 263.1 -160 127.7
US
Abbvie Inc
NYSE:ABBV
365.2B USD 4.5 87.3
US
Amgen Inc
NASDAQ:AMGN
178.1B USD 3.6 22.8
US
Gilead Sciences Inc
NASDAQ:GILD
163.4B USD 3.7 19.2
US
Epizyme Inc
F:EPE
94.1B EUR 966.7 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.7B USD 7.3 27.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.1B USD 5.6 16.5
NL
argenx SE
XBRU:ARGX
41.3B EUR 14.8 37.4
US
Seagen Inc
F:SGT
39.3B EUR 20.8 -61.8
AU
CSL Ltd
ASX:CSL
60.2B AUD 1.5 29.5
P/E Multiple
Earnings Growth PEG
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average P/E: 32.9
23.1
27%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
22.8
20%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
14%
1.2
NL
argenx SE
XBRU:ARGX
37.4
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.5
9%
3.3

Market Distribution

Higher than 88% of companies in China
Percentile
88th
Based on 7 566 companies
88th percentile
7
Low
0 — 1.1
Typical Range
1.1 — 3.4
High
3.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.1
Median 1.9
70th Percentile 3.4
Max 1 129 391.6

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
23.8B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.

Intrinsic Value
86.81 CNY
Undervaluation 33%
Intrinsic Value
Price ¥58.25
X
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett